Discussing the use of tocilizumab in treating COVID-19

Discussing the use of tocilizumab in treating COVID-19 - hero image

Professor Daiana Stolz is joined by Dr Lennie Derde, who was involved in the recent study ‘Interleukin-6 Receptor Antagonists in Critically Ill Patients with Covid-19‘, published by the New England Journal of Medicine. The pair discuss the use of tocilizumab in targeting interleukin-6 and assess its role in reducing the risk of invasive mechanical ventilation for critically ill patients.

Learning objectives

  • To appraise the pathophysiologic link between IL-6 and its antagonism in COVID-19
  • To compile the current evidence supporting IL-antagonists in COVID-19
  • To contrast randomised controlled trials with positive and negative using tocilizumab in COVID-19
  • To distinguish inclusion criteria, time to treatment and posology of tocilizumab in REMAC-CAP and RECOVERY trials
  • To determine who the potential candidates for tocilizumab are
  • To formulate future research directions for IL-6 blockage in COVID-19